15:17 , Mar 30, 2018 |  BC Week In Review  |  Company News

Celgene licenses preclinical candidate from Abide

Celgene Corp. (NASDAQ:CELG) gained exclusive, worldwide rights to preclinical candidate ABX-1772 from Abide Therapeutics Inc. (San Diego, Calif.), and the companies terminated a 2014 deal under which Celgene had rights to ABX-1431, an option to...
22:21 , Mar 28, 2018 |  BC Extra  |  Company News

Celgene, Abide reshuffle partnership

Celgene Corp. (NASDAQ:CELG) gained exclusive, worldwide rights to preclinical candidate ABX-1772 from Abide Therapeutics Inc. (San Diego, Calif.), and the companies terminated a 2014 deal under which Celgene had rights to ABX-1431, an option to...